Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Lymphomas are blood cancer which occur when the white blood cells grow abnormally. Lymphomas are categorized into three main types: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Hodgkin Lymphoma (Hodgkin's disease), and Non-Hodgkin Lymphoma (NHL). The Hodgkin Lymphoma (Hodgkin's disease) involves Reed-Sternberg cells and is less prevalent while the lymphomas which do not involve Reed-Sternberg cells are categorized under Non-Hodgkin Lymphoma (NHL) and are more prevalent then Hodgkin Lymphomas.

Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive (fast-growing) non-Hodgkin lymphoma (NHL) which affects the B-lymphocytes and can develop either in lymph nodes or in ‘extranodal sites’ (areas outside the lymph nodes). When DLBCL reappears or grows again after a period of remission, it is called as ‘relapsed’ while the term ‘refractory’ is used to define the situation when the lymphoma does not respond to treatment

The global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1,364 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).

Figure 1. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Share (%) in Terms of Value, By Region, 2020

Relapsed or Refractory Diffuse Large B-cell Lymphoma  | Coherent Market Insights

Significant prevalence of diffuse large B-cell lymphoma is expected to propel the market growth over the forecast period

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma (NHL). According to the Lymphoma Research Foundation, a U.S.-based nonprofit organization, more than 18,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed every year in the U.S.

Moreover, the Surveillance, Epidemiology, and End Results (SEER) Program, which provides information on cancer statistics among the U.S. population, estimated the percent of cases diagnosed according to the stages which is given in graph below

Figure 2. Diffuse Large B-cell Lymphoma Cases by Stages in the U.S.

Relapsed or Refractory Diffuse Large B-cell Lymphoma  | Coherent Market Insights

Increasing approval of therapeutics for relapsed or refractory diffuse large B-cell lymphoma by regulatory authorities is expected to drive the market growth over the forecast period

Market players are focusing on approvals for relapsed or refractory diffuse large B-cell lymphoma therapeutics from regulatory authorities which is expected to accelerate the market growth. On February 8, 2021, Bristol Myers Squibb, a pharmaceutical company, received approval for lisocabtagene maraleucel (liso-cel, Breyanzi), chimeric antigen receptor (CAR) T-cell therapy, indicated for diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B, in patients who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

request-sample

Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2020: US$ 1,364 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2020 to 2027
Forecast Period 2021 to 2028 CAGR: 4.2% 2028 Value Projection: US$ 1,975.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Others.
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG 

Growth Drivers:
  • Increasing prevalence of diffuse large B-cell lymphoma 
  • Increasing approval of therapeutics for relapsed or refractory diffuse large B-cell lymphoma by regulatory authorities
Restraints & Challenges:
  • Side effects associated with therapeutics for relapsed or refractory diffuse large B-cell lymphoma

Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic

Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 132 million cases and 2.87 million deaths due to coronavirus disease (COVID-19) were reported till April 7, 2021 across the globe.

Rapidly increasing cases of COVID-19 caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs, and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.

According to National Center for Biotechnology Information (NCBI), April 29, 2020, many clinical trials suspended the trial enrollment, in order to minimize the risk of contracting COVID-19 and this has led to the delay in the activation of new clinical trials. Moreover, many companies have already missed the follow-up for the patients already in trials. Furthermore, travel restrictions, patient concerns of contracting coronavirus infection, and others are some of the factors responsible for the withdrawal of patients from the clinical trial.

Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Restraint

However, side effects associated with therapeutics for relapsed or refractory diffuse large B-cell lymphoma are expected to hinder the market growth. For example, common adverse reactions occurring in diffuse large B-cell lymphoma patients when treated with MONJUVI (tafasitamab-cxix) are listed below:

  • Infusion reaction such as headache, shortness of breath, and chills during the infusion of MONJUVI
  • Low blood cell counts of red blood cells, white blood cells, and platelets is common when patients are treated with MONJUVI which can become life threatening
  • The patients can acquire life threatening infections. Patients should inform their doctors if they get fever of 100.4°F (38°C) or above

Apart from the above stated adverse events, common side effects associated with MONJUVI administration includes diarrhea, cough, fever, decreased appetite, respiratory tract infection, swelling of lower legs or hands, and fatigue.

Key Players

Major players operating in the global relapsed or refractory diffuse large B-cell lymphoma market include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG.

Market players are focusing on developing effective therapies for the treatment of relapsed or refractory diffuse large B-cell lymphoma which is expected to fuel the market growth over the forecast period. For instance, in November 2020, ADC Therapeutics SA, a late clinical-stage biotechnology company, announced that its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) had been accepted by the U.S. Food and Drug Administration (FDA). Lloncastuximab tesirine (Lonca) is developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Moreover, in December 2020, Novartis AG, announced analyses of a 40-month median follow-up from the Phase II JULIET trial, according to which Kymriah, a CAR-T cell therapy, showed safety and efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Market Dynamics

Market players are focusing on various inorganic growth strategies such as collaborations and agreements in order to strengthen their market presence which is anticipated to drive the growth of relapsed or refractory diffuse large B-cell lymphoma market. For instance, on June 10, 2020, AbbVie Inc., a publicly traded biopharmaceutical company and Genmab A/S, a biotechnology company, signed a collaboration agreement to develop and commercialize Genmab's early-stage investigational antibody product candidates for cancer. Under this agreement, the companies will commercialize epcoritamab, indicated for B cell malignancies such as diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

Similarly, on June 29, 2020, Karyopharm Therapeutics, Inc., a pharmaceutical company, selected Biologics by McKesson, an independent specialty pharmacy by McKesson Corporation, as a specialty pharmacy provider for XPOVIO, indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)

Key features of the study:

  • This report provides in-depth analysis of the global relapsed or refractory diffuse large B-cell lymphoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global relapsed or refractory diffuse large B-cell lymphoma market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global relapsed or refractory diffuse large B-cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global relapsed or refractory diffuse large B-cell Lymphoma market.

Detailed Segmentation:

  • Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type:
    • Monjuvi
    • XPOVIO
    • Polivy
    • Kymriah
    • Yescarta
    • Others
  • Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Region:
    • North America
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • MorphoSys US Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bristol Myers Squibb
    • Karyopharm Therapeutics
    • Hoffmann-La Roche AG
    • Merck & Co., Inc.
    • Gilead Sciences, Inc.
    • Novartis AG

 “*” marked represents similar segmentation in other categories in the respective section.      

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Safety Syringes for COIVD-19 Vaccines
  5. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Monjuvi  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • XPOVIO
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Polivy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Kymriah
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Yescarta
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • MorphoSys US Inc.  
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol Myers Squibb
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Karyopharm Therapeutics
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Gilead Sciences, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 36 market data tables and 35 figures on "Relapsed or Refractory Diffuse Large B-cell Lymphoma Market” - Global forecast to 2028

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.